Results 131 to 140 of about 48,310 (191)

The BCL-2 protein family: from discovery to drug development. [PDF]

Cell Death Differ
Croce CM, Vaux D, Strasser A, Opferman JT, Czabotar PE, Fesik SW.   +5 more
europepmc   +1 more source

Lobaric Acid Exhibits Anticancer Potential by Modulating the Wnt/β‐Catenin Signaling Pathway in MCF‐7 Cells

Pharmacology Research &Perspectives, Volume 13, Issue 4, August 2025.
Effect of lobaric acid on Wnt/β‐catenin pathway in breast cancer. ABSTRACT Lichen secondary metabolites with many remarkable biological activities are used in cancer treatments due to their low side effects and high anticancer potential. In particular, these metabolites constitute an interesting research area in cancer treatments due to their potential
Şeyda Nur Kalın, Kübra Nur Bayındırlı, Emine Toraman, Şükran Günaydın, Fatmanur Keleş, Ahmet Altay, Harun Budak   +6 more
wiley   +1 more source

Chenodeoxycholic acid triggers gastric mucosal injury by inducing apoptosis and FXR activation. [PDF]

PLoS One
Peng S, Sun R, Liu H, Wang B, Li Y.
europepmc   +1 more source

Management of T‐cell malignancies: Bench‐to‐bedside targeting of epigenetic biology

CA: A Cancer Journal for Clinicians, Volume 75, Issue 4, Page 282-307, July/August 2025.
Abstract The peripheral T‐cell lymphomas (PTCL) are the only disease for which four histone deacetylase (HDAC) inhibitors have been approved globally as single agents. Although it is not clear why the PTCL exhibit such a vulnerability to these drugs, understanding the biological basis for this activity is essential.
Ariana Sabzevari, Johnson Ung, Jeffrey W. Craig, Kallesh D. Jayappa, Ipsita Pal, David J. Feith, Thomas P. Loughran Jr, Owen A. O’Connor   +7 more
wiley   +1 more source

Development of a robust BH3 drug toolkit for precision medicine in hematologic malignancies. [PDF]

Theranostics
Jacquier V, Romero A, Molinaro C, Somayaji R, Abouladze M, Gadacha OK, Ovejero S, de Boussac H, Gabellier L, Davids MS, Moreaux J, Herbaux C.   +11 more
europepmc   +1 more source

Methods for Controlling Small GTPase Activity

ChemBioChem, Volume 26, Issue 13, July 11, 2025.
This concept highlights recent and emerging methods for controlling small GTPase activity, encompassing both small‐molecule‐based approaches and protein engineering strategies. The use of these approaches to advance the understanding of small GTPase function, current limitations, and future outlook is discussed.
Benjamin Faulkner, Yuchen He, Daniel Sitrin, Cliff I. Stains   +3 more
wiley   +1 more source

Pathological Mechanisms Involved in HIV-Associated Lymphomagenesis: Novel Targeted Therapeutic Approaches. [PDF]

Cells
Straista M, Caccuri F, Arnaut N, Caruso A, Slevin M.   +4 more
europepmc   +1 more source

Shexiang Baoxin Pills alleviate doxorubicin-induced cardiotoxicity via the reactive oxygen species-mediated AKT/Bcl-2 pathway. [PDF]

Medicine (Baltimore)
Wang S, Chen M, Qian Y, Chen X, Xu W.
europepmc   +1 more source

Crizotinib Inhibits Viability, Migration, and Invasion by Suppressing the <i>c-Met</i>/<i>PI3K</i>/<i>Akt</i> Pathway in the Three-Dimensional Bladder Cancer Spheroid Model. [PDF]

Curr Oncol
Song B, Kim D, Ho JN, Le VH, Lee S.
europepmc   +1 more source

Roles of Non-Coding RNA in Anthracycline Cardiotoxicity: A Narrative Review. [PDF]

J Inflamm Res
Xiao S, Li Y, Li B, Wang H, Wang K, Yang S.   +5 more
europepmc   +1 more source